Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Ultragenyx Pharmaceutical EBITDA Margin % Related Terms
Ultragenyx Pharmaceutical EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RARE vs VERA, IRON, QURE: EBITDA Margin % Comparison
For the Biotechnology subindustry, Ultragenyx Pharmaceutical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ultragenyx Pharmaceutical EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Ultragenyx Pharmaceutical's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ultragenyx Pharmaceutical (RARE) has a EBITDA Margin % of -113.97% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ultragenyx Pharmaceutical and its competitors. According to the industry distribution chart, Ultragenyx Pharmaceutical ranks #478 out of 939 companies in the Biotechnology industry, placing it in the top 50.9%.
Is Ultragenyx Pharmaceutical's EBITDA Margin % too high?
Ultragenyx Pharmaceutical's current EBITDA Margin % is -113.97%. Based on the distribution chart, Ultragenyx Pharmaceutical ranks #478 out of 939 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ultragenyx Pharmaceutical has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ultragenyx Pharmaceutical's EBITDA Margin % compare to VERA and IRON?
According to the Biotechnology industry distribution chart, Ultragenyx Pharmaceutical ranks #478 out of 939 companies for EBITDA Margin %. This places Ultragenyx Pharmaceutical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ultragenyx Pharmaceutical and its competitors. Ultragenyx Pharmaceutical's current EBITDA Margin % is -113.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ultragenyx Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Ultragenyx Pharmaceutical (RARE) is currently considered Possible Value Trap. The stock's GF Value™ is $47.30, compared to a current price of $33.22 — trading 29.8% below its estimated fair value. The current EBITDA Margin % is -113.97%. Ultragenyx Pharmaceutical's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Ultragenyx Pharmaceutical (RARE), the current EBITDA Margin % is -113.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ultragenyx Pharmaceutical (RARE) Overvalued in 2026?
Based on GuruFocus' analysis, Ultragenyx Pharmaceutical stock appears to be undervalued.
The current stock price of $33.22 is trading 29.8% below its estimated GF Value™ of $47.30.
GuruFocus considers Ultragenyx Pharmaceutical to be Possible Value Trap.
Key valuation signals for RARE:
EBITDA Margin %: -113.97%
GF Value™: $47.30 vs. price of $33.22 (29.8% below fair value)
No single metric tells the full story. See the RARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
70GF Score
Get the complete analysis for RARE
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RARE has been successfully added to your 
